Catalent Inc (CTLT) Stock Fundamental Analysis
NYSE:CTLT - New York Stock Exchange, Inc. - US1488061029 - Common Stock - Currency: USD
Overall CTLT gets a fundamental rating of 3 out of 10. We evaluated CTLT against 195 industry peers in the Pharmaceuticals industry. CTLT may be in some trouble as it scores bad on both profitability and health. CTLT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CTLT was profitable.
In the past year CTLT had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CTLT reported negative net income in multiple years.
In the past 5 years CTLT always reported a positive cash flow from operatings.
1.2 Ratios
CTLT has a Return On Assets of -4.25%. This is in the better half of the industry: CTLT outperforms 78.01% of its industry peers.
The Return On Equity of CTLT (-11.66%) is better than 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROIC | N/A |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTLT has a Gross Margin (21.82%) which is comparable to the rest of the industry.
CTLT's Gross Margin has declined in the last couple of years.
CTLT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
2. Health
2.1 Basic Checks
CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTLT has been increased compared to 1 year ago.
The number of shares outstanding for CTLT has been increased compared to 5 years ago.
Compared to 1 year ago, CTLT has a worse debt to assets ratio.
2.2 Solvency
CTLT has an Altman-Z score of 1.62. This is a bad value and indicates that CTLT is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.62, CTLT is doing good in the industry, outperforming 64.92% of the companies in the same industry.
The Debt to FCF ratio of CTLT is 49.84, which is on the high side as it means it would take CTLT, 49.84 years of fcf income to pay off all of its debts.
CTLT has a Debt to FCF ratio of 49.84. This is in the better half of the industry: CTLT outperforms 78.01% of its industry peers.
CTLT has a Debt/Equity ratio of 1.38. This is a high value indicating a heavy dependency on external financing.
CTLT has a worse Debt to Equity ratio (1.38) than 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Altman-Z | 1.62 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
A Current Ratio of 2.51 indicates that CTLT has no problem at all paying its short term obligations.
CTLT has a Current ratio (2.51) which is in line with its industry peers.
A Quick Ratio of 1.93 indicates that CTLT should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.93, CTLT is in line with its industry, outperforming 44.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
CTLT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.40%.
Measured over the past years, CTLT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -33.48% on average per year.
CTLT shows a small growth in Revenue. In the last year, the Revenue has grown by 4.71%.
Measured over the past years, CTLT shows a quite strong growth in Revenue. The Revenue has been growing by 11.71% on average per year.
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
3.2 Future
The Earnings Per Share is expected to grow by 73.38% on average over the next years. This is a very strong growth
CTLT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.44% yearly.
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 288.55, CTLT can be considered very expensive at the moment.
78.01% of the companies in the same industry are more expensive than CTLT, based on the Price/Earnings ratio.
CTLT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.28.
The Price/Forward Earnings ratio is 41.25, which means the current valuation is very expensive for CTLT.
CTLT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CTLT is cheaper than 76.44% of the companies in the same industry.
CTLT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CTLT is valued a bit cheaper than 76.96% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CTLT is valued a bit cheaper than 78.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 116.39 | ||
| EV/EBITDA | 36.47 |
4.3 Compensation for Growth
CTLT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTLT's earnings are expected to grow with 113.64% in the coming years.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y148.11%
EPS Next 3Y113.64%
5. Dividend
5.1 Amount
CTLT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
63.48
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners92.2%
Inst Owner Change-91.8%
Ins Owners0.48%
Ins Owner Change0%
Market Cap11.52B
Analysts52.86
Price Target64.77 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-149.78%
Min EPS beat(2)-336.02%
Max EPS beat(2)36.46%
EPS beat(4)1
Avg EPS beat(4)-365.14%
Min EPS beat(4)-1032.86%
Max EPS beat(4)36.46%
EPS beat(8)2
Avg EPS beat(8)-208.81%
EPS beat(12)5
Avg EPS beat(12)-141.22%
EPS beat(16)9
Avg EPS beat(16)-103.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-5.19%
Max Revenue beat(2)4.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-6.04%
Max Revenue beat(4)4.16%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)-0.33%
Revenue beat(16)8
Avg Revenue beat(16)-0.03%
PT rev (1m)0.11%
PT rev (3m)4.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.12%
EPS NY rev (1m)4.18%
EPS NY rev (3m)-6.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 | ||
| P/S | 2.61 | ||
| P/FCF | 116.39 | ||
| P/OCF | 28.88 | ||
| P/B | 3.25 | ||
| P/tB | 31.57 | ||
| EV/EBITDA | 36.47 |
EPS(TTM)0.22
EY0.35%
EPS(NY)1.54
Fwd EY2.42%
FCF(TTM)0.55
FCFY0.86%
OCF(TTM)2.2
OCFY3.46%
SpS24.36
BVpS19.51
TBVpS2.01
PEG (NY)0.82
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% | ||
| FCFM | 2.24% |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Debt/EBITDA | 11.05 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 6.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 90.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 1.62 |
F-Score5
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)125.99%
Cap/Depr(5y)159.79%
Cap/Sales(3y)11.57%
Cap/Sales(5y)13.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
EBIT growth 1Y-166.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year196.68%
EBIT Next 3Y58.17%
EBIT Next 5Y41.23%
FCF growth 1Y121.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.85%
OCF growth 3Y-14.78%
OCF growth 5Y1.59%